Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
Corporate Information Processa Pharmaceuticals, Inc. (“Processa,” “we” or the “Company”) was incorporated under the laws of the State of Delaware on March 29, 2011. Our principal executive office is located at 601 21 st Street, Suite 300 Vero Beach, FL 32960. Our telephone number is (772) 453-2899. 4 We make available free of charge on or through our Internet website ( http://www.processapharmaceuticals.com) our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (SEC), as well as our Code of Ethics and Code of Conduct. The SEC also maintains a website which provides online access to reports and other information regarding registrants that file electronically with the SEC at: www.sec.gov. The information contained on our website and social media channels is not included as a part of, or incorporated by reference into, this report. Overview We are a publicly listed clinical-stage biopharmaceutical company. We are developing a pipeline of Next Generation Cancer therapy (“NGC”) small molecules, one of which is currently in a Phase 2 trial, while the other is in pre-clinical development.
Read the full filing description · filed 18 Mar 2026
At a glance
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- CEO
- George Ng
- Incorporated in
- DE
Source: SEC filings. Information and analytics, not investment advice.